Arca
Skip to content
Tools
Tools

Voltage-gated T-type calcium channel

Family in Homo sapiens that 8 drugs act on.

  • Drugs that act on it: 8
  • Approved: 6
  • In phases 1 to 3: 2
  • Sponsors: 5
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CACNA1G, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8

Approved6

  • Ethosuximide
  • Mibefradil
  • Methsuximide
  • Paramethadione
  • Phensuximide
  • Trimethadione

Phase 30

    Phase 22

    • Apinocaltamide
    • Suvecaltamide

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Idorsia Pharmaceuticals Ltd.113%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Voltage-gated T-type calcium channel blocker; the rest name their own mechanism.
      EthosuximideApprovedPfizerSmall moleculeBlocker2
      MibefradilWithdrawnApprovedCavionSmall moleculeBlocker1
      MethsuximideApprovedPfizerSmall moleculeBlocker0
      ParamethadioneApprovedAbbVieSmall moleculeBlocker0
      PhensuximideApprovedPfizerSmall moleculeBlocker0
      TrimethadioneApprovedAbbVieSmall moleculeBlocker0
      ApinocaltamidePhase 2Idorsia Pharmaceuticals Ltd.Small moleculeBlocker0
      SuvecaltamidePhase 2Jazz PharmaceuticalsSmall moleculeModulatorVoltage-gated T-type calcium channel modulator0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyMibefradil—Not yet recruitingFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineDec 4, 2025
      Ketogenic Diet for New-Onset Absence EpilepsyEthosuximidePhase 3RecruitingJohns Hopkins UniversityFeb 18, 2020
      Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel SyndromeEthosuximidePhase 3RecruitingTanta UniversityJan 3, 2020

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2362995, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.